Malaria Vaccines: What we need for success

1
Malaria VaccinesWhat we need for success
Christian Loucq, MD Director, PATH Malaria
Vaccine Initiative 8 July 2008 UK All-Party
Parliamentary Malaria Group
2
Why Im Here To Answer Three Questions

• What is the PATH Malaria Vaccine Initiative
  (MVI)?
• Why a vaccine?
• What will it take?

3
To accelerate the development of malaria vaccines
and ensuretheir availability and accessibility
in the developing world
A world free from malaria
Founded in 1999 Donors Bill Melinda Gates
FoundationUS Agency for International
Development, ExxonMobil, private individuals
4
To accelerate the development of malaria vaccines
and ensuretheir availability and accessibility
in the developing world

• Availability
• Global access
• Regulatory policy pathways
• Accessibility
• Preparing countries for the vaccine introduction
• Decision-making framework

A world free from malaria
5
MVI A global programof PATH
6
Why a Malaria Vaccine?
7
Why a Malaria Vaccine?Age Distribution of Severe
Malaria
Gupta et al., Nature Medicine 5 340-342, 1999
0.14 0.12 0.1 0.08 0.06 0.04 0.02 0
Proportion Affected
1-2 mos
3-4 mos
5-6 mos
6-12 mos
1 2 3 4 5
6 7 8 9
Age group
8
Targeting the Parasite Lifecycle
9
Research and Development Strategy
10
Phase 1a Phase 1/2a
Phase 1b
Phase 2b
Construct Selection
Process Development
Final Formulation
Toxicology
GSK RTS,S AS01/AS02
Sanaria PfSPZ
Product Candidates
Targets P. vivax
Pre-erythroctyic (liver)
Pre-erythroctyic (liver)
ICGEB/BBIL PvRII
LaTrobe MSP2 ISA720
GenVec Ad5-CSP LSA1Ag2 Ad5-MSP1 AMA1
Monash MSP4
Blood-stage
MVDB AMA1-C1 ISA720
Research Programs
WRAIR/GSK AMA1 AS01/AS02
Adjuvanted Recombinant Proteins Viral
Vectored Live Attenuated (weakened)
11
RTS,S Clinical Research Center Network
IRSS - Centre Muraz
KHRC, Kintampo KCCR, Kumasi
KEMRI - Kisumu
HAS, Lambarene
KEMRI - Kilifi
JMP, Korogwe
IHDRC, Bagamoyo
KCH, Lilongwe
CISM, Manhiça
RTS,S MVI-GSK Program in Africa
12
WHO Vaccine PrioritizationVaccines that may be
licensed by 2012(WHO SAGE, November 2007)
Weighted priority score based upon expert opinion
13
Sanaria A Different Approach

• Targets the whole parasite
• Uses a live, attenuated parasite

14
Challenges What will it take?

• No vaccine against a parasite
• No known correlates of immunity
• No market

15
What will it take? Strong partners
16
What will it take? Sustained commitment
17
Partners Today and Tomorrow
18

• What can you do?
• Support investments in malaria control today
• Advocate now for investments in the tools for
  tomorrow
• And